Antibody engineering for increased potency, breadth and half-life

Current Opinion in HIV and AIDS
Stuart A SieversPamela J Bjorkman

Abstract

This review highlights recent developments in HIV-1 antibody engineering and discusses the effects of increased polyreactivity on serum half-lives of engineered antibodies. Recent studies have uncovered a wealth of information about the relationship between the sequences and efficacies of anti-HIV-1 antibodies through a combination of bioinformatics, structural characterization and in vivo studies. This knowledge has stimulated efforts to enhance antibody breadth and potency for therapeutic use. Although some engineered antibodies have shown increased polyreactivity and short half-lives, promising efforts are circumventing these problems. Antibodies are desirable as therapeutics due to their ability to recognize targets with both specificity and high affinity. Furthermore, the ability of antibodies to stimulate Fc-mediated effector functions can increase their utility. Thus, mAbs have become central to strategies for the treatment of various diseases. Using both targeted and library-based approaches, antibodies can be engineered to improve their therapeutic properties. This article will discuss recent antibody engineering efforts to improve the breadth and potency of anti-HIV-1 antibodies. The polyreactivity of engineered HIV-1...Continue Reading

References

Apr 26, 1994·Proceedings of the National Academy of Sciences of the United States of America·C F BarbasD R Burton
Mar 1, 1996·European Journal of Immunology·V GhetieE S Ward
Mar 21, 2003·Protein Engineering·Teemu KorpimäkiPetri Saviranta
Mar 21, 2003·Nature·Xiping WeiGeorge M Shaw
Jul 10, 2003·Autoimmunity Reviews·Gisele Zandman-Goddard, Yehuda Shoenfeld
Aug 16, 2003·Science·Hedda WardemannMichel C Nussenzweig
Mar 25, 2004·Trends in Immunology·Abner Louis Notkins
Jun 3, 2005·Nature·Christopher C GoodnowCarola G Vinuesa
Jun 28, 2005·Nucleic Acids Research·Andreas Bohne-Lang, Claus-Wilhelm von der Lieth
Feb 1, 2006·The Journal of Experimental Medicine·Makoto TsuijiHedda Wardemann
Apr 7, 2006·Protein Science : a Publication of the Protein Society·Louis A ClarkHerman Van Vlijmen
Dec 19, 2006·Nature Biotechnology·Consuelo Garcia-RodriguezJames D Marks
Jul 24, 2007·Current Opinion in Biotechnology·Shaun M Lippow, Bruce Tidor
Sep 25, 2007·Nature Biotechnology·Shaun M LippowBruce Tidor
Jun 25, 2008·Proceedings of the National Academy of Sciences of the United States of America·Rodrigo BarderasJ Ignacio Casal
Oct 30, 2008·Proceedings of the National Academy of Sciences of the United States of America·Weizao ChenDimiter S Dimitrov
Dec 23, 2008·Biochimica Et Biophysica Acta·Gary R MatyasCarl R Alving
Jul 3, 2009·Proceedings of the National Academy of Sciences of the United States of America·Naresh ChennamsettyBernhardt L Trout
Jan 19, 2010·Nature Biotechnology·Jonathan ZalevskyJohn R Desjarlais
Mar 4, 2010·Protein Science : a Publication of the Protein Society·R Blake PepinskyEllen Garber
Jun 5, 2010·PLoS Pathogens·Joshua S Klein, Pamela J Bjorkman

❮ Previous
Next ❯

Citations

Dec 4, 2015·Biotechnology Journal·Julia ZischewskiRainer Fischer
Jan 31, 2017·Immunological Reviews·Amarendra PeguNancy L Haigwood
Feb 13, 2018·Yonsei Medical Journal·Soo Jin OhOk Sarah Shin
Sep 7, 2017·Protein Engineering, Design & Selection : PEDS·Martin Klinger
Aug 29, 2019·Frontiers in Immunology·Audrey L ButlerGalit Alter
Sep 13, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Yanan WangJunjie Chen
Nov 25, 2020·Current Opinion in HIV and AIDS·Pilar MendozaChristian Gaebler
Feb 19, 2021·Experimental Biology and Medicine·Nneka Pu KorieOsbourne Quaye
Feb 2, 2016·Advanced Drug Delivery Reviews·Casey K Hua, Margaret E Ackerman
Jun 10, 2021·Protein Science : a Publication of the Protein Society·Zhaoyong XiRieko Ishima
Jul 16, 2020·ACS Chemical Biology·Rebecca M LimJianming Xie

❮ Previous
Next ❯

Methods Mentioned

BETA
glycosylation
targeted mutations

Software Mentioned

Glyprot

Related Concepts

Related Feeds

Bacteriophage: Phage Therapy

Phage therapy uses bacterial viruses (bacteriophages) to treat bacterial infections and is widely being recognized as an alternative to antibiotics. Here is the latest research.

© 2021 Meta ULC. All rights reserved